v3.26.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Income Statement [Abstract]          
Net revenues $ 193,399 $ 167,204 $ 551,038 $ 481,003 $ 655,353
Cost of revenues 44,529 44,729 124,564 124,722 166,879
Gross profit 148,870 122,475 426,474 356,281 488,474
Operating costs and expenses:          
Research, development and clinical studies 58,099 54,029 167,883 163,639 224,544
Sales and marketing 53,297 58,546 173,338 171,404 240,064
General and administrative 43,645 45,921 169,406 134,645 177,666
Total operating costs and expenses 155,041 158,496 510,627 469,688 642,274
Operating income (loss) (6,171) (36,021) (84,153) (113,407) (153,800)
Financial income (expenses), net (1,709) 5,999 (5,437) 18,111 17,550
Income (loss) before income tax (7,880) (30,022) (89,590) (95,296) (136,250)
Income tax 2,555 7,248 7,641 16,432 (23)
Net income (loss) $ (10,435) $ (37,270) $ (97,231) $ (111,728) $ (136,227)
Basic net income (loss) per ordinary share (in usd per share) $ (0.09) $ (0.33) $ (0.84) $ (1.00) $ (1.22)
Diluted net income (loss) per ordinary share (in usd per share) $ (0.09) $ (0.33) $ (0.84) $ (1.00) $ (1.22)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) 116,785,198 111,908,252 115,685,559 111,259,532 111,471,991
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) 116,785,198 111,908,252 115,685,559 111,259,532 111,471,991